Apraclonidine (ALO 2145) is a selective α2 and weak α1 receptor agonist that effectively lowers intraocular pressure (IOP) in human eyes. Apraclonidine is a topical ophthalmic solution [1] [2].

Apraclonidine hydrochloride (ALO 2145) is more commonly used topically for glaucoma, as it penetrates the cornea and blood-brain barrier to a lesser extent and therefore has fewer adverse systemic effects [2].

Apraclonidine hydrochloride (ALO 2145) is effective in animal models of elevated IOP and glaucoma in humans. The ocular hypotensive effects of Apraclonidine are usually attributed to reduced aqueous humor synthesis and vasoconstrictor actions at the anterior segment branches of the ophthalmic artery. Apraclonidine (1.15%, single instillation) inhibits 98% of PGE2-induced aqueous flare elevationy [2] [3]. Animal Model: male rabbits [3] Dosage: 1.15% Administration: Apraclonidine (1.15%, single instillation) Result: Inhibited PGE2-induced elevation of aqueous flare in pigmented rabbits.